Jul. 4, 2011
Shenzhen Relin Medicine, a leading Chinese ophthalmic pharmaceutical company, and MingSight Pharmaceuticals, a US based R&D company, announced the formation of a JV to develop and commercialize an innovative treatment for diabetic eye disease in China on July 5, 2011. The JV is focused on developing MS-553, a new chemical entity that has the potential to become a first-in-class oral therapy for diabetic eye disease. The JV acquired the exclusive rights in China to MS-553 from MingSight, which previously in-licensed the compound from Pfizer through an exclusive worldwide licensing agreement.
To facilitate the global development of MS-553, the joint venture will adhere to the development standards of both the Chinese SFDA and the US FDA as MS-553 advances through clinical proof-of-concept.